For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Lecanemab Accepted for US Review, Action Date Set for January: Eisai/Biogen
July 7, 2022
- Opdivo Top-Selling Drug for 6 Months on End: Encise June Data
July 7, 2022
- Astellas CEO Sees Lower SGA and Trial Costs and Higher Research and Manufacturing Outlays Post-COVID
July 6, 2022
- Mitsubishi Tanabe Recalls Tranquilizer Depas over Contamination
July 6, 2022
- Kitasato Pharma to Be Dissolved at September-End: Meiji
July 6, 2022
- Astellas, Mogrify Ink Regenerative Medicine Collab for Sensorineural Hearing Loss
July 6, 2022
- Astellas Looks to Beat Innovation Malaise through Organizational and HR Rejig
July 6, 2022
- Shionogi Starts Document Submission for COVID Pill in China
July 5, 2022
- BMS Japan Launches New Head Office as It Looks to Spur Ideas through Casual Chats
July 5, 2022
- High Court Verdict for Bayer Employee Damage Suit Set for Sept. 7, Settlement Eyed Too
July 5, 2022
- Aculys, KNOCK ON THE DOOR Form Comprehensive Epilepsy Alliance
July 5, 2022
- Promotions via In-Hospital Seminars in HP Market Rise 28.4% YOY in May: Intage
July 5, 2022
- Chugai Best-Paying Japan Pharma in FY2021, 25 Drug Makers Pay Average 8.33 Million Yen
July 4, 2022
- UCB Japan Snaps Up Zogenix Japan, Employees Too
July 4, 2022
- AstraZeneca Japan Taps Ex-Takeda Japan Oncology Head as New Chief
July 4, 2022
- Fujifilm to Inject US$1.6 Billion to Rev Up Biopharma CDMO Biz
July 1, 2022
- Mitsubishi Tanabe Seeks Congenital CMV Nod for Valixa Dry Syrup
July 1, 2022
- AbbVie Japan Files Skyrizi for Palmoplantar Pustulosis
July 1, 2022
- Blood Cancer Drug Pegaspargase Filed in Japan: Nihon Servier
July 1, 2022
- Sanofi Seeks Dupixent Label Expansion for Prurigo Nodularis in Japan
July 1, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…